BACKGROUND: Preoperative neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have prognostic value in patients with various operable tumors. The aim of our study was to determine whether NLR and PLR are predictive of survival in thymic carcinoma patients after complete resection. METHODS: A total of seventy-nine patients who underwent complete resection of thymic carcinoma at our hospital between January 2005 and December 2015 were retrospectively enrolled. Differential leukocyte counts were collected before surgery, and the relationships of NLR, PLR, and other patient clinical variables with survival were estimated by Cox regression analysis and Kaplan-Meier survival analysis. RESULTS: Univariate analysis found that a high level of NLR was associated with lower disease-free survival (DFS) (HR: 3.385, 95% CI: 1.073-10.678, P=0.037) and lower overall survival (OS) (HR: 12.836, 95% CI: 1.615-101.990, P=0.016). The optimal NLR threshold of 4.1 could stratify the patients with high risk of recurrence or metastasis (P=0.026) and death (P=0.006). Meanwhile, the NLR value of >4.1 in those patients was associated with bigger tumor size (P=0.035) and more advanced Masaoka stages (P=0.040) compared with NLR ≤4.1. However, the PLR and other variables were not significantly associated with survival in thymic carcinoma patients. CONCLUSIONS: The preoperative NLR of >4.1 was significantly associated with larger tumor size, more advanced Masaoka stages and reduced DFS and OS, but was not an independent predictor of survival in thymic carcinoma patients after complete resection.
BACKGROUND: Preoperative neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have prognostic value in patients with various operable tumors. The aim of our study was to determine whether NLR and PLR are predictive of survival in thymic carcinomapatients after complete resection. METHODS: A total of seventy-nine patients who underwent complete resection of thymic carcinoma at our hospital between January 2005 and December 2015 were retrospectively enrolled. Differential leukocyte counts were collected before surgery, and the relationships of NLR, PLR, and other patient clinical variables with survival were estimated by Cox regression analysis and Kaplan-Meier survival analysis. RESULTS: Univariate analysis found that a high level of NLR was associated with lower disease-free survival (DFS) (HR: 3.385, 95% CI: 1.073-10.678, P=0.037) and lower overall survival (OS) (HR: 12.836, 95% CI: 1.615-101.990, P=0.016). The optimal NLR threshold of 4.1 could stratify the patients with high risk of recurrence or metastasis (P=0.026) and death (P=0.006). Meanwhile, the NLR value of >4.1 in those patients was associated with bigger tumor size (P=0.035) and more advanced Masaoka stages (P=0.040) compared with NLR ≤4.1. However, the PLR and other variables were not significantly associated with survival in thymic carcinomapatients. CONCLUSIONS: The preoperative NLR of >4.1 was significantly associated with larger tumor size, more advanced Masaoka stages and reduced DFS and OS, but was not an independent predictor of survival in thymic carcinomapatients after complete resection.
Entities:
Keywords:
Thymic carcinoma; neutrophil-lymphocyte ratio (NLR); platelet-lymphocyte ratio (PLR); prognosis
Authors: Michael J Proctor; Paul G Horgan; Dinesh Talwar; Colin D Fletcher; David S Morrison; Donald C McMillan Journal: Cancer Date: 2013-04-10 Impact factor: 6.860
Authors: Jeffrey A Forquer; Nan Rong; Achilles J Fakiris; Patrick J Loehrer; Peter A S Johnstone Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-08 Impact factor: 7.038
Authors: Daniel Valdivia; Danjouma Cheufou; Benjamin Fels; Stephan Puhlvers; Khaled Mardanzai; Mohamed Zaatar; Gerhard Weinreich; Christian Taube; Dirk Theegarten; Martin Stuschke; Martin Schuler; Georgios Stamatis; Balazs Hegedus; Clemens Aigner Journal: Pathol Oncol Res Date: 2021-04-21 Impact factor: 3.201
Authors: Stefan Janik; Thomas Raunegger; Philipp Hacker; Bahil Ghanim; Elisa Einwallner; Leonhard Müllauer; Ana-Iris Schiefer; Julia Moser; Walter Klepetko; Hendrik Jan Ankersmit; Bernhard Moser Journal: Oncotarget Date: 2018-04-24